Danmei Pang

791 total citations
17 papers, 357 citations indexed

About

Danmei Pang is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Danmei Pang has authored 17 papers receiving a total of 357 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Danmei Pang's work include Cancer Treatment and Pharmacology (6 papers), Advanced Breast Cancer Therapies (5 papers) and HER2/EGFR in Cancer Research (4 papers). Danmei Pang is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Advanced Breast Cancer Therapies (5 papers) and HER2/EGFR in Cancer Research (4 papers). Danmei Pang collaborates with scholars based in China, Canada and United States. Danmei Pang's co-authors include Jifeng Feng, Xiaojia Wang, Binghe Xu, Si Sun, Joseph Ragaz, Qunling Zhang, Zhongsheng Tong, Zefei Jiang, Minhao Fan and Jin Li and has published in prestigious journals such as Journal of Clinical Oncology, PLANT PHYSIOLOGY and International Journal of Cancer.

In The Last Decade

Danmei Pang

14 papers receiving 353 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Danmei Pang China 7 196 151 117 113 43 17 357
Chester Kao United States 8 164 0.8× 160 1.1× 110 0.9× 108 1.0× 28 0.7× 19 330
M. D’Arcangelo Italy 12 200 1.0× 196 1.3× 119 1.0× 79 0.7× 30 0.7× 31 360
Peter Schirmacher Germany 9 239 1.2× 265 1.8× 143 1.2× 189 1.7× 32 0.7× 17 470
Peter Houghton United States 8 150 0.8× 165 1.1× 171 1.5× 76 0.7× 53 1.2× 20 400
Özge Gümüşay Türkiye 11 164 0.8× 124 0.8× 100 0.9× 78 0.7× 20 0.5× 42 350
Erion Dobi France 14 217 1.1× 147 1.0× 74 0.6× 111 1.0× 28 0.7× 31 356
Nishi Kothari United States 12 238 1.2× 155 1.0× 93 0.8× 74 0.7× 63 1.5× 29 372
Davide Bosso Italy 12 132 0.7× 167 1.1× 133 1.1× 70 0.6× 21 0.5× 18 366
Yuji Shimoda Japan 10 210 1.1× 132 0.9× 133 1.1× 229 2.0× 99 2.3× 26 410
Aurélie Ferru France 11 250 1.3× 82 0.5× 93 0.8× 86 0.8× 84 2.0× 30 439

Countries citing papers authored by Danmei Pang

Since Specialization
Citations

This map shows the geographic impact of Danmei Pang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danmei Pang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danmei Pang more than expected).

Fields of papers citing papers by Danmei Pang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danmei Pang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danmei Pang. The network helps show where Danmei Pang may publish in the future.

Co-authorship network of co-authors of Danmei Pang

This figure shows the co-authorship network connecting the top 25 collaborators of Danmei Pang. A scholar is included among the top collaborators of Danmei Pang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danmei Pang. Danmei Pang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Dun, S.L., Qifeng Zhou, Wen Xia, et al.. (2025). Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer. npj Breast Cancer. 11(1). 123–123.
2.
3.
Pan, Qiuzhong, Haomiao Li, Xianan Li, et al.. (2023). Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial. EClinicalMedicine. 64. 102240–102240. 17 indexed citations
4.
Zhang, Yuehua, et al.. (2022). Survival and clinicopathological significance of blood vessel invasion in operable breast cancer: a systematic review and meta-analysis. Japanese Journal of Clinical Oncology. 53(1). 35–45. 3 indexed citations
5.
Zhao, Jianli, Yaping Yang, Danmei Pang, et al.. (2020). Development and validation of a nomogram in survival prediction among advanced breast cancer patients. Annals of Translational Medicine. 8(21). 1446–1446. 2 indexed citations
6.
Wang, Xi, Shusen Wang, Heng Huang, et al.. (2020). Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).. Journal of Clinical Oncology. 38(15_suppl). 507–507. 14 indexed citations
7.
8.
Hu, Qian, et al.. (2020). Comparison of regulatory networks of E74‑like factor 1 and cold‑shock domain‑containing E1 in breast cancer cell lines using ChIP datasets. Experimental and Therapeutic Medicine. 20(6). 1–1. 3 indexed citations
9.
Wang, Jiayu, Yujian Shi, Tao Sun, et al.. (2019). Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes. Cancer Medicine. 8(5). 2074–2084. 17 indexed citations
10.
Lin, Kairong, Danmei Pang, Yabin Jin, et al.. (2018). Circulating CD8+ T-cell repertoires reveal the biological characteristics of tumors and clinical responses to chemotherapy in breast cancer patients. Cancer Immunology Immunotherapy. 67(11). 1743–1752. 28 indexed citations
11.
Hu, Qian, Xiao Lin, Danmei Pang, et al.. (2018). ARHGAP42 promotes cell migration and invasion involving PI3K/Akt signaling pathway in nasopharyngeal carcinoma. Cancer Medicine. 7(8). 3862–3874. 31 indexed citations
12.
Pang, Danmei, Qian Hu, Yingxin Lin, et al.. (2018). The novel long non‑coding RNA PRNCR1‑2 is involved in breast cancer cell proliferation, migration, invasion and cell cycle progression. Molecular Medicine Reports. 19(3). 1824–1832. 14 indexed citations
13.
Wang, Yanjie, et al.. (2017). [Effects of Modified Ruji Recipe in Preventing Relapse and Metastasis of Breast Cancer Patients with Negative Hormone Receptor].. PubMed. 37(2). 169–173. 2 indexed citations
14.
15.
16.
Hu, Xichun, Jian Zhang, Binghe Xu, et al.. (2014). Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. International Journal of Cancer. 135(8). 1961–1969. 218 indexed citations
17.
Hu, Xichun, Jian Zhang, Binghe Xu, et al.. (2013). BP40 MULTICENTER PHASE II STUDY OF APATINIB, A NOVEL INHIBITOR OF VEGFR, IN HEAVILY PRETREATED PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER. The Breast. 22. S33–S33. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chester Kao Breakdown of academic impact, for papers by M. D’Arcangelo Breakdown of academic impact, for papers by Peter Schirmacher Breakdown of academic impact, for papers by Peter Houghton Breakdown of academic impact, for papers by Özge Gümüşay Breakdown of academic impact, for papers by Erion Dobi Breakdown of academic impact, for papers by Nishi Kothari Breakdown of academic impact, for papers by Davide Bosso Breakdown of academic impact, for papers by Yuji Shimoda Breakdown of academic impact, for papers by Aurélie Ferru
Rankless by CCL
2026